PUUSTELLI-GROUP
19.3.2020 09:28:05 CET | Business Wire | Press release
Puustelli has innovated a unique furniture system to eliminate moisture problems in bathroom fittings. The furniture frames feature a structure made of biocomposite by injection moulding. The biocomposite is a mixture of polypropylene and chemical pulp fibre, and is a water-resistant, non-toxic, ecological, modifiable and lasting material. This Finnish product innovation has been developed and is made 100% in Finland. The furniture system, which is suitable for kitchen furniture, has been in production in Puustelli Miinus kitchens since back in 2013. Puustelli was granted a European patent for its invention in 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005234/en/
Water-resistant material
Most bathroom fittings typically have a frame of MDF or particleboard, both of which have poor moisture resistance. The biocomposite frame in Puustelli bathroom fittings can fully withstand water and comes with a 30-year guarantee.
Low-emission concept
Formaldehyde is also present in the panel materials typically used in bathroom fittings. When emitted into the indoor air, formaldehyde is harmful to the health. Even when the panel structure is only slightly damaged, the impact of moisture multiplies the harmful effects. The Puustelli biocomposite frame has a formaldehyde content of exactly 0%. Not only that, the biocomposite is antistatic and does not attract dust.
Ecological solution
Once a frame made from conventional furniture board has absorbed moisture, it can no longer be repaired and must be disposed of and replaced. The Puustelli biocomposite frame on the other hand is a fully reusable and recyclable material. Since it is recyclable, any waste raw material originating in the manufacturing process of the Puustelli biocomposite frame can be efficiently reused.
Puustelli bioframe can be modified
Unlike traditional frame materials, the Puustelli bioframe doesn’t tire of modification or being moved. The frame has precise dimensional accuracy and fittings and materials that affect its appearance can be switched around numerous times if required without the screw fastenings becoming fatigued. The furniture is available for large and small spaces alike. The frames can be finished in various ways depending on the range. Puustelli has also developed from the composite for the frame, a design end panel with a restrained pattern suitable for different styles. Small locators have also been made in the panel in conjunction with injection moulding to make it easy to screw the end panel accurately into the ready-made holes in the frame. The bioframes of the washbasin cupboards have been designed for careful use of space. Plumbing has also been taken into account and if necessary can easily be accessed later. Base cabinets come at a height of 613 mm and widths vary between 200 mm and 1200 mm depending on the model. Since the depth is just 370 mm, they can fit into small spaces.
“The bathroom product development process has been long and at times challenging, but the outcome was well worth all the work. Following our kitchen furniture, a similar bathroom fitting innovation was already anticipated and is now in production,” says Jussi Aine, CEO, Puustelli Group Oy.
Puustelli Group Oy is a Finnish family enterprise and part of the century-old Harjavalta Group, which also includes Kastelli Group Oy and Lapti Group Oy. The Group had a turnover of €491 million in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
